- Home
- TRAD vs MXCT Comparison
TRAD vs MXCT Comparison
Compare TRAD & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRAD | MXCT |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.1M | 136.2M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRAD | MXCT |
|---|---|---|
| Price | $10.04 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 2.0K | ★ 331.9K |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.93 | $0.64 |
| 52 Week High | $10.08 | $1.86 |
Technical Indicators
Market Signals| Indicator | TRAD | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 29.53 |
| Support Level | $9.99 | $0.98 |
| Resistance Level | $10.08 | $1.27 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 60.00 | 16.20 |
Price Performance
Historical ComparisonAbout TRAD APEX Tech Acquisition Inc. Ordinary Shares
APEX Tech Acquisition Inc is a blank check company.
About MXCT MaxCyte Inc.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.